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Objectives: To evaluate the cost-utility of apixaban vs warfarin in patients 
with atrial fibrillation (AF) from the Peruvian Social Security (EsSalud) perspec-
tive. MethOds: A validated Markov decision model was adapted from EsSalud´s 
perspective. For efficacy and safety inputs, the model is based on data from the 
ARISTOTLE trial and clinical trials of warfarin therapy for AF. Resource utilization 
and costing of events were estimated using a reference hospital´s billing records 
and validated with local experts. Costs of procedures were obtained from official 
EsSalud tariffs. The costs of medications were obtained from SEACE. All costs 
are presented at 2014 nuevos soles. A discount rate of 3.5% was used for both 
costs and outcomes. A cohort of 1,000 patients was modeled using a lifetime 
horizon. Probabilistic sensitivity analysis (PSA) as well as univariate sensitivity 
analyses were performed. Results: The following outcomes were estimated: Total 
Ischemic Stroke (non-fatal mild, non-fatal moderate, non-fatal severe, fatal) apixa-
ban: 147 vs. warfarin: 161. Total hemorrhagic stroke (non-fatal mild, non-fatal 
moderate, non-fatal severe, fatal) apixaban: 14 vs. warfarin 26. Other major bleeds 
(non-fatal GI bleeds, non-fatal non ICH or non GI related major bleeds, fatal): 
apixaban: 66 vs. warfarin: 85. Warfarin therapy resulted in a quality-adjusted life 
expectancy of 6.19 years at a cost of S/. 14,744. Treatment with apixaban led to 
a quality-adjusted life expectancy of 6.50 years at a cost of S/. 27,473. The cost-
utility ratio was calculated at S/. 41,296 per QALY. Our findings were robust in 
univariate sensitivity analyses varying model inputs across plausible ranges. In 
Monte Carlo analysis, apixaban was cost-effective in 70% of simulations using the 
recommended threshold for WHO of 3 GDP per capita. cOnclusiOns: Apixaban 
is a cost-effective alternative relative to warfarin for secondary stroke prevention 
in patients with AF treated at EsSalud.
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Objectives: To assess the cost-effectiveness of monotherapy with a phosphodi-
esterase-5 (PDE-5) inhibitor, an endothelin receptor antagonist (ERA), or a pros-
tanoid versus supportive care in patients with pulmonary arterial hypertension 
(PAH); and, to assess the cost-effectiveness of add-on combination therapy versus 
monotherapy PAH drugs. MethOds: A cost utility analysis based on a Markov 
model was designed to estimate costs and efficacy of both PAH monotherapy 
in treatment naïve patients and add-on therapies for treatment experienced 
patients. Separate analyses were conducted by PAH functional class (II, III). The 
primary outcome measure was the number of quality adjusted life years (QALYs) 
associated with treatment. Transition probabilities, based on the relative risk of 
improving and worsening in functional class with treatment versus placebo, were 
derived from a concurrent network meta-analysis. Utility values and costs were 
obtained from published data and clinical expert opinion. Extensive determinis-
tic sensitivity analyses and probabilistic analysis were conducted. Results: For 
monotherapy versus supportive care, in the base case, sildenafil is considered 
the most cost-effective therapy for patients with PAH in functional class II and 
III. Tadalafil was also less costly and more effective than supportive care in func-
tional class II and III; however, sildenafil was dominant over tadalafil. There were 
no studies comparing monotherapy with a PDE-5 inhibitor to add-on therapy. 
At a decision-maker’s willingness to pay of less than ~$88,000 per QALY, neither 
add-on therapy with an ERA plus tadalafil nor add-on therapy with an ERA plus 
riociguat would be considered cost effective in patients with PAH in functional 
class II and III relative to an ERA alone. Despite the uncertainty in the clinical 
inputs, the probabilistic sensitivity analysis showed that apart from sildenafil and 
tadalafil, the other PAH therapies had negligible probability of being the most cost 
effective. cOnclusiOns: Sildenafil is considered the most cost-effective therapy 
for patients with PAH in functional class II and III.
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Objectives: To characterize Medicare patients with acute ischemic stroke (AIS) 
and describe healthcare resource utilization and associated direct costs during 
one-year pre-admission and follow-up period. MethOds: Medicare beneficiaries 
ages 65+ years with an incident AIS hospitalization in 2011 were identified from 
the 5% random Medicare Limited Data Set. Resources utilized and expenditures 
for hospitalizations, ICU stays, outpatient visits, rehabilitation, ER visits, and by 
types of services were measured during five phases: (1) pre-admission; (2) hospi-
talization to one-month; (3) 2- to 3-months; (4) 4- to 6-months; and (5) 7-months 
to 1-year. The differences in the mean annual costs pre- and post-AIS were com-
pared. Results: We identified 6,697 AIS patients (age 79±8.0), 614 (9.2%) who were 
readmitted within 30 days. Resource utilization and costs in all categories were 
highest during the first 30 days and decreased progressively during follow up. The 
average cost per patient during hospitalization to one-month period was $16,219. 
The average cost was $4,588 at 2- to 3-months; $4,650 at 4- to 6-months; and 
$7,426 at 7-months to 1-year period. The average annual cost in the year following 
AIS was $32,882 per patient. The three highest annual average cost drivers were 
diagnostic/lab services ($27,263), followed by inpatient hospitalization ($19,226), 
Objectives: Venous thromboembolism (VTE), including deep vein thrombo-
sis (DVT) and pulmonary embolism (PE), is a common cardiovascular disorder. 
Acute VTE is typically managed with a short course parenteral anticoagulation 
followed by 3-6 months vitamin-K antagonist. Novel oral anticoagulants do not 
require routine anticoagulation monitoring and dose adjustments, thus poten-
tially providing an alternative treatment option. The cost-effectiveness of dabi-
gatran etexilate vs. edoxaban was evaluated over six months of treatment in the UK 
care setting. MethOds: A life-time Markov model was used, evaluating costs and 
quality-adjusted life years (QALY) of recurrent VTE (rVTE) and VTE-related deaths, 
and most common adverse events during anticoagulation treatment, major or clini-
cally relevant bleeds (MCRB). The efficacy and safety of dabigatran were based on 
the pooled RE-COVER treatment studies, and indirectly compared with results of 
The Hokusai Study for edoxaban. Utility estimates for rVTE, bleedings and long-
term consequences of VTE were sourced from RE-COVER studies, and from the 
literature. Costs were analyzed from the perfective of the NHS and PSS. Results: 
Following index VTE, six months treatment with dabigatran etexilate was less costly 
and improved patients’ quality of life when compared with six months edoxa-
ban, assuming equal drug costs. Dabigatran projected more rVTEs overall, but less 
number of non-fatal PEs; dabigatran had less MCRB, hence the additional costs of 
rVTE were compensated by cost savings from avoidance of bleedings. Probabilistic 
sensitivity analyses showed 60% likelihood for dabigatran to be considered cost-
effective at a willingness-to-pay of £30,000. Evaluating the model for treatment 
in a Western-European population, with efficacy and safety from corresponding 
sub-groups of RE-COVER studies, and The Hokusai Study, dabigatran etexilate was 
projected to be less expensive and to improve patients’ quality of life compared with 
edoxaban. cOnclusiOns: Dabigatran etexilate was projected less costly and safer 
than edoxaban when administered for six months following VTE.
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does AzilsArtAn medoximil – ChlorthAlidone loWer risk 
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Objectives: The study objective was to investigate and compare the relative costs 
and effects of using azilsartan medoximil – chlorthalidone, a newly approved com-
bination therapy in comparison to existing olmesartan medoximil – hydrochlor-
thiazide in treating mild to moderate essential hypertension, using the third party 
payer perspective and the risk of developing coronary heart disease (CHD) in 10 
years. MethOds: A decision tree analysis was done using Tree Age Pro®. Cost evalu-
ations included direct medical costs i.e. drug cost, cost of medical care (general phy-
sician and specialist visits) and cost to treat the adverse events, hospitalization and 
laboratory services over a time frame of one year. Cost values were obtained from 
the Red book 2010 and literature. Effectiveness was calculated by the reduction in 
SBP which was obtained, from various randomized controlled trials for these drugs. 
Incremental cost effectiveness ratio (ICER) was calculated. Monte Carlo simulation 
and probabilistic sensitivity analysis was done to further validate our findings. 
The risk of getting CHD in the next 10 years was calculated using Framingham risk 
score. Results: Outcomes favored azilsartan (8.51 mm Hg) with a total expected 
cost for treatment as $4759.46 to olmesartan (6.71 mm Hg) with a total cost as 
$4949.48. The ICER was 105.07. Patients on azilsartan have a 12% risk and patients on 
olmesartan have a 26% risk of developing CHD in the next 10 years. cOnclusiOns: 
This study showed that patients with mild/moderate essential hypertension on 
azilsartan have a lower risk of developing CHD when compared to those on olm-
esartan. Azilsartan is a cost effective therapy compared to olmesartan, in treating 
mild/moderate hypertension, from a third party payer perspective.
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Objectives: It is estimated that up to 400,000 persons in Mexico are hospitalized 
yearly for deep-vein thrombosis (DVT). DVT refers to the presence of a thrombus in 
the deep vein system. The main objective was to compare the treatment costs of 
tinzaparin, enoxaparin and nadroparin of patients with DVT from the institutional’s 
view in Mexico. MethOds: We developed a cost-minimization model by using out-
comes and resource utilization data from an indirect treatment comparison (no 
head-to-head trials compare these treatments) of patients with DVT. We found 
that recurrence and major bleeding was equally effective in all the LMWHs. Only 
direct medical costs were used, such as medications and adverse events; these were 
obtained from the portal shop by IMSS and also from their unitary costs. To prove 
the strength of the analysis, deterministic sensitivity analysis was performed; all 
the quantities are expressed in Mexican pesos (MXP) at 2014 Results: Tinzaparin 
sodium showed to be the less expensive LMWH for 10 days treatment of DVT; the 
savings resulted compared with nadroparin and enoxaparin were $670.44 hasta 
$1,111.40 respectively. Tinzaparin sodium reduced 28.48% of nadroparin total cost 
and 40.18% of enoxaparin total cost. ensitivity analysis did not change the con-
clusion that tinzaparium sodium is less expensive than nadroparin and enoxa-
parin (varying patient weight, duration of treatment and considering medication 
waste). cOnclusiOns: Tinzaparin sodium has the highest mean molecular weight 
(approximately 6,500 Da) of the commercially available LMWHs and is least depend-
ent on renal clearance. In addition, tinzaparin sodium strategy is less expensive than 
the LMWHs strategy for the inpatient treatment of DVT in Mexico.
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older adults MethOds: Medicare beneficiaries participated in the 2007 HRS pre-
scription drug survey and 2009 HRS well-being survey and enrolled in Medicare part 
D (stand-alone), HMO, fee-for service or Advantage plans. The study sample includes 
773 individuals with at least one of four common chronic health conditions and 
responded both years. Random intercept logit model was estimated for medica-
tion non-adherence and population based generalized estimating equation was 
utilized to examine poverty-adjusted well-being (excluding out-of-pocket medical 
expenditure from poverty threshold) Results: Preliminary results indicate that 
individuals having inertia in plan switching were 3.4 times more likely to be non-
adherent to regular prescription medications compared to those without inertia 
(odds ratio estimate, 3.4 with p< 0.001). Neither switching from brand name drug to 
generic drug plan nor plan level switching appeared to be a significant predictor of 
medication non-adherence or economic well-being in this group. cOnclusiOns: 
Consumer inertia rather switching decision appears to be a significant factor influ-
encing medication non-adherence among individuals with four common chronic 
health conditions
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ComPliAnCe And Control of hyPertension With Co-morbidities in 
PrimAry CAre in UkrAine
Korzh O.
Kharkov Medical Academy of Postgraduate Education, Kharkov, Ukraine
Objectives: The aim of this study was to evaluate adherence of family doctors to 
National Clinical Practice Guideline (2012) in the management of hypertension with 
co-morbidities in Ukraine. MethOds: Cross-sectional study was done at a primary 
care network in Ukraine. Total 62 physicians and 1550 patients’ prescriptions written 
by same physicians (25 prescriptions per physician) were analyzed. All patients had 
hypertension with co-morbidities. Depending on the recommendations of National 
Clinical Practice Guideline (2012), the prescriptions were clustered as compliant and 
non-compliant prescriptions. All obtained data were analyzed using descriptive 
and inferential statistics. Results: A statistically significant negative association 
(r= -0.089, p= 0.005) was observed between hypertension control and co-morbidities. 
Compliant patients had statistically weak negative association (r= -0.078, p= 0.015) 
with patients having co-morbidities (38.2%). No statistically significant association 
was observed between guideline adherence and any other co-morbidity. Majority 
of the patients received guidelines-compliant pharmacotherapy. The overall good 
level of physician compliance with National Clinical Practice Guideline (2012) was 
observed in the management of hypertension with co-morbidities. cOnclusiOns: 
The study explored several features of prescription pattern of the primary care 
physicians involved in the management of hypertension with co-morbidities and 
recognized the need for improvement in their prescription pattern for treating the 
hypertension.
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Objectives: EQ-5D and SF-6D can both be used to derive health utility scores. 
Variations in utility scores can have a major impact on the results of cost-util-
ity studies. This study aimed to compare the health utility of acute coronary 
syndrome (ACS) patients from Malaysia measured by the two descriptive sys-
tems MethOds: Data was obtained from an earlier study. The study collected data 
from ACS patients admitted to the Sarawak General Hospital who consented to 
the study. Validated language versions of the EQ-5D-3L and SF-36v1 were admin-
istered during admission and 12-months post-admission. Health utility scores 
were calculated using the Malaysian EQ-5D-3L utility tariff and Brazier SF-6D 
algorithm. Patient demographic and clinical data were extracted from medi-
cal records. Results: Data from 100 of 112 subjects were usable for analysis. 
Mean age of patients was 56.3 years and 88% were male. Utility scores meas-
ured by EQ-5D were higher than those measured by SF-6D. Mean utility scores 
from EQ-5D and SF-6D during admission were 0.75 and 0.56 (p< 0.0001); and 0.82 
and 0.79 (p= 0.0521) 12 months post-admission, respectively. Improvement in 
utility scores from baseline to 12 months was statistically significant for both 
EQ-5D (0.06, p= 0.0300) and SF-6D (0.23, p< 0.001). EQ-5D and SF-6D utilities were 
moderately correlated at 12 months (r= 0.68, p< 0.0001) but not during admission 
(r= 0.12, p= 0.2183). Ceiling effect was observed in EQ-5D utility scores, whereby 
22% and 29% of patients reported the best possible EQ-5D health state during 
admission and 12 months, respectively. Only 3% recorded the highest SF-6D utility 
at 12 months. cOnclusiOns: Consistent with past studies, utility scores of ACS 
patients calculated by EQ-5D (Malaysian value set) and SF-6D (Brazier algorithm) 
resulted in different utility values, magnitude of change and extent of ceiling 
effect. Properties of patient reported outcome instruments should also be consid-
ered when selection utility measures for cost-effectiveness studies.
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Objectives: With a lack of an essential evidence on utilities to support cost-effec-
tiveness analysis of hypertension management in Vietnam, we aimed to gather 
data on health utilities for hypertensive patients and identify predictors of util-
ity. MethOds: Hypertensive patients, from 40 to 80 years old visiting the hospital 
were invited to take a survey. Short-form 36 version 2 translated into Vietnamese 
was used to interview patients. We applied a specific published model to measure 
utilities, that explains a reasonable share of variance, especially in those cases when 
only relatively small differences in health are expected. Results: 712 patients were 
included in the study. Mean utility of these patients was 0.72 +/- 0.14. Controlling 
and pharmacy/IV therapy services ($9,484). Average cost per patient in all cat-
egories at 1-year post-AIS increased significantly from the pre-admission period. 
Diagnostic/lab services expenditures increased $20,225; pharmacy/IV therapy 
services increased $6,864; and outpatient visits increased $2,484; all p-values < 
0.001. Compared to the overall AIS patients, the early readmitted patients expe-
rienced higher resource utilization and expenditures. cOnclusiOns: Economic 
burden of Medicare AIS patients is substantial. Resource utilization and direct 
costs were highest during the first 30 days of AIS hospitalization and doubles in 
the first year. Costs significantly increased in the year following stroke compared 
to the pre-admission year.
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Objectives: This study quantified the total direct healthcare costs of aortic and 
mitral valvular disease to insurers and patients, stratified by asymptomatic and 
symptomatic disease status. MethOds: Using 1996-2011 data from the Medical 
Expenditure Panel Survey (MEPS), a large, nationally-representative database from 
the US, this study performed descriptive analyses of the total annual healthcare 
costs to insurers and patients for aortic and mitral valve disease. The healthcare 
costs were reported at the individual and US aggregate levels. Individuals with aortic 
and mitral valve disease were identified by International Classification of Disease 
Codes, 9threvision and stratified as either symptomatic or asymptomatic based on 
the presence of comorbid conditions. Results: The MEPS database included 148 
patients with aortic disease and 1,057 with mitral valve disease. Asymptomatic 
patients comprised 64% and 70% of the population for aortic disease and mitral 
valve disease, respectively. Symptomatic aortic disease patients incurred higher 
overall annual healthcare direct costs per patient compared to asymptomatic 
patients ($30,146 vs. $16,065). Symptomatic mitral valve disease patients incurred 
greater annual healthcare costs per patient compared to asymptomatic patients 
($14,054 vs. $7,198). Because these were direct costs, the majority of the health-
care expenditures were borne by the insurer (range 79% to 90% based on type of 
disease and symptom status) rather than the patient. When aggregated to the US 
population, the overall annual direct cost was $4.5 billion and $10 billion for aortic 
disease and mitral valve disease, respectively. Approximately 75% and 52% of the 
total annual direct cost was attributed to symptomatic aortic valve and mitral valve 
disease patients, respectively. cOnclusiOns: These findings indicate that the total 
direct healthcare costs of valvular disease are quite large. Symptomatic patients 
incur disproportionately greater healthcare costs, possibly due to costly surgical 
interventions required to treat their valvular disease.
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PersistenCe And ComPliAnCe With liPid- loWering drUgs in PAtients 
With ChroniC kidney diseAse
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Objectives: Among individuals suffering from chronic kidney disease (CKD) newly 
treated with lipid-lowering drugs (LLD): (1) to estimate persistence with LLD one 
year after treatment initiation; (2) among those persisting, to estimate compliance 
in the year following LLD initiation; (3) to identify factors associated with persis-
tence and with compliance. MethOds: Using Quebec administrative databases we 
carried out a cohort study of individuals aged ≥ 18 who had started a LLD between 
January 1, 2000 and December 31, 2011. Individuals still undergoing treatment with 
any LLD one year after their first claim were considered persistent. Of these, we 
considered compliant those with a supply of drugs for ≥ 80% of days. We identified 
factors associated with persistence and with compliance using modified Poisson 
regression. Results: Among 14,607 eligible individuals, 80.7% were persistent and 
88.7% of these were compliant with their LLD. Individuals with low (Prevalence ratio: 
1.03; 95%IC: 1.01-1.06) and medium socioeconomic status (SES) (1.04; 1.02-1.05) com-
pared with those with high SES, treated by a nephrologist (vs. general practitioner) 
(1.06; 1.04-1.09), who had hypertension (1.04; 1.02-1.06), diabetes (1.04; 1.03-1.06), 
stroke (1.09; 1.07-1.12) or coronary disease (1.07; 1.05-1.09) were more likely to be 
persistent. Individuals more likely to be compliant were aged ≥ 66 (vs. 18-65) (1.04; 
1.01-1.07), had low (vs. high) SES (1.08; 1.06-1.10), and had ≥ 12 (vs. < 7) distinct drugs 
(1.03; 1.0-1.05), had been hospitalized (1.04; 1.02-1.06) or had stroke (1.04; 1.03-1.06) 
in the year prior to LLD treatment initiation. cOnclusiOns: One year after LLD 
initiation, 28% of individuals with CKD were either no longer taking their treatment 
or had not been compliant to it. Results could help target individuals who need help 
to better manage their LLD treatment.
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Well-being of mediCAre benefiCiAries enrolled in PArt d PlAns
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Objectives: It is not well understood the relative impacts of switching (from brand 
name drug to generic drug or plan switching) and consumer inertia on medication 
non-adherence and economic well-being for individuals with at least four most 
common chronic conditions: diabetes, hypertension, heart disease and psychiatric 
problem. The goal of the current study is to examine the whether switching decision 
or consumer inertia impact medication adherence and/or economic well-being of 
